A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection Josephine MauskopfLieven AnnemansErik Smets Review Article 14 October 2012 Pages: 1 - 16
Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era Mark A. BoydAndrew M. Hill Review Article 14 October 2012 Pages: 17 - 34
The Impact of Disease Stage on Direct Medical Costs of HIV Management Adrian LevyKarissa JohnstonJulio Montaner Review Article 14 October 2012 Pages: 35 - 47
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden Ola GhatnekarCatharina HjortsbergMickael Löthgren Original Research Article 14 October 2012 Pages: 49 - 57
The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France Xavier ColinAntoine LafumaPascal Guillon Original Research Article 14 October 2012 Pages: 59 - 68
Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients Andrew M. HillBonaventura ClotetErik Smets Original Research Article 14 October 2012 Pages: 69 - 81
Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA Josephine MauskopfAnita BroganErik Smets Original Research Article 14 October 2012 Pages: 83 - 105
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK Karen MoeremansLieven AnnemansErik Smets Original Research Article 14 October 2012 Pages: 107 - 128
US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial Anita BroganJosephine MauskopfErik Smets Original Research Article 14 October 2012 Pages: 129 - 146
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK Karen MoeremansLindsay HemmettErik Smets Original Research Article 14 October 2012 Pages: 147 - 167
Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts Andrew M. HillKelly GeboErik Smets Original Research Article 14 October 2012 Pages: 169 - 181
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France Xavier ColinAntoine LafumaPascal Guillon Original Research Article 14 October 2012 Pages: 183 - 197
